This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940 · clinicaltrials.gov ↗

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Development program terminated

Conditions

Head and Neck Cancer
Melanoma
HPV-Related Malignancy
HPV-Related Carcinoma
HPV-Related Cervical Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Lung Cancer, Nonsmall Cell
Melanoma (Skin)

Interventions

DIAGNOSTIC_TEST: Tumor Profiling

Sponsor

Repertoire Immune Medicines